GLP-1 receptor agonists are the most consequential drug class to emerge in obesity and type-2 diabetes since metformin. The category started with exenatide and liraglutide, broke commercial ceilings with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and is now expanding into orals (orforglipron, oral semaglutide), triple agonists (retatrutide), and amylin combinations (cagrisema, eloralintide).
The signal worth tracking has shifted. Weight loss alone is no longer the headline — secondary indications are. SELECT showed a 20% drop in major adverse cardiovascular events for non-diabetic adults with obesity. A Mass General Brigham analysis in JAMA reported 42–58% lower heart-failure hospitalizations in HFpEF. AAN 2026 added migraine, dementia incidence, and Parkinson's signals to the growing list. The Phase 3 EVOKE Alzheimer's trial, by contrast, missed its endpoint.
Browse the latest below, or filter by drug at #semaglutide, #tirzepatide, #orforglipron, and #retatrutide.
A presentation at the American Academy of Neurology 2026 meeting (closing April 22) reported that in 10,997 chronic migraine patients initiating GLP-1 agonists versus an equal topiramate cohort, GLP-1 users were 10% less likely to visit the ED (23.7% vs 26.4%), 14% less likely to be hospitalized, 42% less likely to start CGRP monoclonal antibodies, and 48% less likely to start valproate over 12 months — adding migraine to the growing list of GLP-1 secondary benefits.
IQVIA tracking data reported April 21 showed Eli Lilly's newly-launched oral GLP-1 Foundayo (orforglipron) drew 1,390 prescriptions in its first full week (April 6-10), roughly 45% of the 3,071 Wegovy pill scripts in Novo Nordisk's launch week in January. Analyst consensus requires Foundayo to hit about 5.4 million prescriptions from April-December to generate $1.7 billion in 2026 revenue — a target that looks challenging at the current trajectory.
Eli Lilly shares closed down nearly 2% at $918.56 and Novo Nordisk fell ~4% on April 22 after CVS Health's decision to opt out of the Medicare obesity drug coverage pilot triggered CMS to scrap the BALANCE model. The combined market cap loss across the two GLP-1 leaders exceeded $25 billion. Hims & Hers dropped another 6% on continued Amazon One Medical competitive pressure.
Telehealth rival Hims & Hers Health shares slid 6% April 21-22 after Amazon's One Medical launched a comprehensive GLP-1 weight management program offering Wegovy and Foundayo starting at $25/month with insurance or $149/month cash-pay for oral options. The move positions Amazon against established telehealth obesity care providers (Hims, Ro, LifeMD, Noom) as the compounded-GLP-1 era winds down.
Amazon One Medical launched a nationwide GLP-1 Management Program offering Wegovy, Zepbound, and Lilly's Foundayo starting at $25/month with insurance, plus $149/month cash-pay for oral drugs and $299/month for injectables. Same-day delivery in nearly 3,000 cities, expanding to 4,500 by year-end. Shares of Eli Lilly, Novo Nordisk, and Hims & Hers fell on the news.
Obesity biotech Kailera Therapeutics priced an upsized IPO of 39.06 million shares at $16, raising $625 million — the largest venture-backed biopharmaceutical IPO since Acelyrin in 2023. Lead candidate ribupatide (a GLP-1/GIP peptide dual agonist) drove 18% body weight loss at 48 weeks in a late-stage Chinese study; global Phase 3 readout expected in 2028.
A living systematic review presented at the American Academy of Neurology 2026 Annual Meeting integrating Phase 2/3 trials and real-world data from 2+ million individuals with diabetes found GLP-1 receptor agonist use was associated with a 20-35% lower incidence of dementia versus DPP-4 or SGLT2 inhibitors. Effect was strongest for semaglutide, despite the EVOKE Phase 3 Alzheimer's trial missing its cognitive endpoint.
The first definitive Phase 3B head-to-head trial of Lilly's tirzepatide versus Novo Nordisk's semaglutide in 750 patients with obesity over 72 weeks showed tirzepatide produced 21.6% mean weight loss vs semaglutide's 15.4%. 36.2% of tirzepatide patients achieved ≥25% weight loss vs 19.4% on semaglutide. Results published April 20 give Lilly a clear comparative data point in the GLP-1 market share battle.
April 20, 2026 is the CMS application deadline for Medicare Part D plans to participate in the BALANCE Model, which will offer Wegovy, Zepbound KwikPen, and Foundayo at $50 copay with a $245/month net price starting July 1. CMS added Foundayo to the Medicare GLP-1 Bridge on April 6 following FDA approval, extending coverage to Lilly's new oral GLP-1.
A study published in Medical Xpress analyzed 5,741 days of AI-powered dietary-tracking data from 332 adults with overweight or obesity. GLP-1 users consumed significantly less energy (1,102 vs 1,281 kcal/day) and protein (53.8 vs 62.0 g/day) than non-users. Weight-adjusted daily protein intake was 0.6 g/kg/day among GLP-1 users, with 88% falling below the Italian national 0.9 g/kg/day recommendation. IRCCS San Raffaele researchers warn of nutritional deficiencies and muscle-health risks during GLP-1 therapy.
Richard DiMarchi and Matthias Tschöp — whose work enabled Eli Lilly's Zepbound and the modern GLP-1 class — published a peer-reviewed draft paper arguing that targeting GIP and glucagon receptors alone, without GLP-1, may deliver comparable weight loss without the nausea and vomiting that plague current therapies. The experimental molecule, backed by BlueWater Biosciences, challenges the central dogma of obesity drug design. Results are preclinical and must still translate to humans.
Omada Health published results from a 12-week study of 245 adults with obesity comparing its GLP-1 Care Track behavioral program (151 members) to a control group (94). Omada members lost 1.8x more total weight (6.0% vs 3.3% of starting weight), 2.1x more body fat, and saw increased muscle mass percentage and improved mental health scores. The finding directly addresses sarcopenia concerns highlighted in recent NPR coverage of GLP-1 discontinuation.
A Cell Reports Medicine study presenting four preclinical experiments and a proof-of-concept clinical trial reports that GLP-1 medicines predominantly reduce body fat alongside a small but significant decrease in lean body mass in obese mice and humans. Among lean tissues, loss of liver mass exceeds change in muscle mass, and while absolute muscle mass and strength decrease, relative muscle mass and strength improve — translating into better running performance in mice.
Novo Nordisk and OpenAI announced a partnership to deploy AI across R&D, manufacturing, and corporate functions, with pilot programs launching immediately and full integration targeted by end of 2026. The deal positions Novo to analyze complex datasets, identify new drug candidates, and compress R&D timelines as it fights to claw back market share from Eli Lilly. OpenAI will also provide AI literacy training to Novo's global workforce.
An NPR investigation found fewer than 1 in 4 patients stay on GLP-1 medications after a year, with most planning to restart later. Researchers warn that up to 40% of weight lost on GLP-1s is lean muscle, and cycling on and off the drugs may accelerate sarcopenia. When patients stop, fat regains rapidly while muscle recovery is uncertain.
A study of 220,043 patients published in Diabetes, Obesity and Metabolism found that combining GLP-1 receptor agonists with SGLT2 inhibitors reduced all-cause mortality by 29%, the cardiovascular composite outcome by 19%, and heart failure risk by 22% compared to SGLT2 inhibitor use alone over 1.3 years of median follow-up.
Mechanistic data from the REMODEL trial presented at the 2026 World Congress of Nephrology showed semaglutide decreased renal fat, lowered arterial resistance, and stabilized cortical fibrosis. Biopsies revealed reduced immune cells around glomeruli, and transcriptomic analysis identified glomerular endothelial cells as the most responsive cell type to treatment.
The FDA published updated guidance clarifying compounding requirements now that semaglutide and tirzepatide shortages have been resolved. The statement reaffirmed enforcement deadlines for 503A and 503B pharmacies while acknowledging ongoing legal challenges from the Outsourcing Facilities Association.